GlassScriptPhysician profile
Mohammad Samir Diab
NPI 1194767087
$67,150.29
in general payments reported to CMS, 2019-2025
37 companies · $12K in 2025
The $12K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,719 · 2021: $4,058 · 2022: $8,102 · 2023: $8,519 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $12K · Consulting Fee: $2,258 · Education: $348 · Travel and Lodging: $72.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,350.00 |
| Food and Beverage | $12,474.95 |
| Consulting Fee | $2,257.50 |
| Education | $347.58 |
| Travel and Lodging | $72.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35,790.83 | 2020-2025 | Otezla, Otezla |
| Celgene Corporation | $7,928.63 | 2019 | |
| Sun Pharmaceutical Industries INC. | $7,338.79 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $3,526.76 | 2022-2025 | Sotyktu |
| Abbvie INC. | $2,817.46 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,852.94 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $1,109.03 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $981.61 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $921.54 | 2019-2025 | |
| Lilly USA, LLC | $902.31 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $676.72 | 2021-2025 | |
| Dermavant Sciences, INC. | $647.48 | 2022-2024 | Vtama |
| Blueprint Medicines Corporation | $423.09 | 2025 | Ayvakit |
| Incyte Corporation | $311.88 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $256.29 | 2020-2025 | Nemluvio, Aklief |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $242.67 | 2019-2025 | Bimzelx, Cimzia |
| Almirall LLC | $225.24 | 2021-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $196.14 | 2021-2025 | Libtayo, Dupixent |
| Organon LLC | $165.92 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $133.27 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $124.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.92 | 2023-2024 | Spevigo |
| Kyowa Kirin, INC. | $57.11 | 2023-2025 | Poteligeo |
| Verrica Pharmaceuticals INC. | $46.91 | 2024-2025 | Ycanth |
| Chiesi USA, INC. | $39.00 | 2024 | Filsuvez |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.22 | 2021-2024 | Cabtreo |
| Krystal Biotech INC | $37.22 | 2024-2025 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $30.32 | 2020 | |
| Smith+Nephew, INC. | $29.13 | 2024-2025 | Grafix Pl |
| Epi Health, LLC | $18.74 | 2022 | |
| Journey Medical Corporation | $17.48 | 2023 | |
| Sandoz INC. | $16.64 | 2023 | Hyrimoz |
| Biofrontera INC. | $16.31 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $15.92 | 2025 | |
| Allergan, INC. | $15.80 | 2021 | |
| Genentech USA, INC. | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Diab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.